Glutamate-Based Antidepressants: Preclinical Psychopharmacology

Trullas, 1990, Functional antagonists at the NMDA receptor complex exhibit antidepressant actions, Eur J Pharmacol, 185, 1, 10.1016/0014-2999(90)90204-J Chaki, 2013, mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants, Neuropharmacology, 66, 40, 10.1016/j.neuropharm.2012.05.022 Machado-Vieira, 2012, Novel glutamatergic agents for major depressive disorder and bipolar disorder, Pharmacol Biochem Behav, 100, 678, 10.1016/j.pbb.2011.09.010 Hashimoto, 2009, Emerging role of glutamate in the pathophysiology of major depressive disorder, Brain Res Rev, 61, 105, 10.1016/j.brainresrev.2009.05.005 Sanacora, 2012, Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders, Neuropharmacology, 62, 63, 10.1016/j.neuropharm.2011.07.036 Szewczyk, 2012, Investigational NMDA receptor modulators for depression, Expert Opin Investig Drugs, 21, 91, 10.1517/13543784.2012.638916 Zarate, 2006, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch Gen Psychiatry, 63, 856, 10.1001/archpsyc.63.8.856 Preskorn, 2008, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder, J Clin Psychopharmacol, 28, 631, 10.1097/JCP.0b013e31818a6cea Skolnick, 2009, Glutamate-based antidepressants: 20 years on, Trends Pharmacol Sci, 30, 563, 10.1016/j.tips.2009.09.002 Machado-Vieira, 2009, Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders, Curr Pharm Des, 15, 1595, 10.2174/138161209788168010 Wheal, 1998, Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity, Prog Neurobiol, 55, 611, 10.1016/S0301-0082(98)00026-4 Kennedy, 2000, Signal-processing machines at the postsynaptic density, Science, 290, 750, 10.1126/science.290.5492.750 Maj, 1992, The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test, Pol J Pharmacol Pharm, 44, 337 Przegalinski, 1997, Antidepressant-like effects of a partial agonist at strychnine- insensitive glycine receptors and a competitive NMDA receptor antagonist, Neuropharmacology, 36, 31, 10.1016/S0028-3908(96)00157-8 Poleszak, 2007, Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test, Pharmacol Rep, 59, 595 Layer, 1995, Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715), Pharmacol Biochem Behav, 52, 621, 10.1016/0091-3057(95)00155-P Li, 2011, Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure, Biol Psychiatry, 69, 754, 10.1016/j.biopsych.2010.12.015 Maeng, 2008, Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, Biol Psychiatry, 63, 349, 10.1016/j.biopsych.2007.05.028 Kos, 2005, A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice, Behav Pharmacol, 16, 155, 10.1097/00008877-200505000-00004 Zarate, 2006, A double-blind, placebo-controlled study of memantine in the treatment of major depression, Am J Psychiatry, 163, 153, 10.1176/appi.ajp.163.1.153 Rogoz, 2002, Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats, Neuropharmacology, 42, 1024, 10.1016/S0028-3908(02)00055-2 Engin, 2009, Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models, Neuroscience, 161, 359, 10.1016/j.neuroscience.2009.03.038 Popik, 2008, Lack of persistent effects of ketamine in rodent models of depression, Psychopharmacology (Berl), 198, 421, 10.1007/s00213-008-1158-z Koike, 2011, Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression, Behav Brain Res, 224, 107, 10.1016/j.bbr.2011.05.035 Lindholm, 2012, The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf(+/−) heterozygous null mice, Neuropharmacology, 62, 391, 10.1016/j.neuropharm.2011.08.015 Autry, 2011, NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses, Nature, 475, 91, 10.1038/nature10130 Bechtholt-Gompf, 2011, CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy, Psychopharmacology (Berl), 215, 689, 10.1007/s00213-011-2169-8 Zarate, 2012, Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression, Biol Psychiatry, 72, 331, 10.1016/j.biopsych.2012.03.004 Szewczyk, 2012, Authors' response: The differences in AMPA receptor dependence on antidepressant-like activity, Expert Opin Investig Drugs, 21, 584 Papp, 1993, New evidence for the antidepressant activity of MK-801, a non- competitive antagonist of NMDA receptors, Pol J Pharmacol, 45, 549 Papp, 1994, Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression, Eur J Pharmacol, 263, 1, 10.1016/0014-2999(94)90516-9 Redmond, 1999, Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity, Eur Neuropsychopharmacol, 9, 165, 10.1016/S0924-977X(98)00023-6 Willner, 1997, Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation, Psychopharmacology (Berl), 134, 319, 10.1007/s002130050456 Garcia, 2009, Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats, Prog Neuropsychopharmacol Biol Psychiatry, 33, 450, 10.1016/j.pnpbp.2009.01.004 Skolnick, 1996, Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression, Pharmacopsychiatry, 29, 23, 10.1055/s-2007-979537 Skolnick, 2001, Current perspectives on the development of non-biogenic amine-based antidepressants, Pharmacol Res, 43, 411, 10.1006/phrs.2000.0806 Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9 Diazgranados, 2010, A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression, Arch Gen Psychiatry, 67, 793, 10.1001/archgenpsychiatry.2010.90 Krystal JH, Sanacora G, Duman RS (in press): Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry. Ibrahim, 2012, A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder, J Clin Psychopharmacol, 32, 551, 10.1097/JCP.0b013e31825d70d6 Siwek, 2009, Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study, J Affect Disord, 118, 187, 10.1016/j.jad.2009.02.014 Nowak, 2003, Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study, Pol J Pharmacol, 55, 1143 Eby, 2006, Rapid recovery from major depression using magnesium treatment, Med Hypotheses, 67, 362, 10.1016/j.mehy.2006.01.047 Zarate CA Jr, Mathews D, Lobna I, Chaves JF, Marquart C, Ukoh I, et al. (2012): A randomized trial of a low trapping non-selective N-methyl-D-aspartate (NMDA) channel blocker in major depression [published online ahead of print November 30]. Biol Psychiatry. Addy, 2009, Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease, J Clin Pharmacol, 49, 856, 10.1177/0091270009336735 Li, 2010, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Science, 329, 959, 10.1126/science.1190287 Alt, 2006, A role for AMPA receptors in mood disorders, Biochem Pharmacol, 71, 1273, 10.1016/j.bcp.2005.12.022 Quirk, 2002, LY404187: A novel positive allosteric modulator of AMPA receptors, CNS Drug Rev, 8, 255, 10.1111/j.1527-3458.2002.tb00228.x Li, 2001, Antidepressant-like actions of an AMPA receptor potentiator (LY392098), Neuropharmacology, 40, 1028, 10.1016/S0028-3908(00)00194-5 Farley, 2010, Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm, Int J Neuropsychopharmacol, 13, 1207, 10.1017/S1461145709991076 Alt, 2005, AMPA receptor potentiators as novel antidepressants, Curr Pharm Des, 11, 1511, 10.2174/1381612053764814 Legutko, 2001, Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator, Neuropharmacology, 40, 1019, 10.1016/S0028-3908(01)00006-5 Bagetta, 1996, N-methyl-D-aspartate and non-N-methyly-D-asapartate receptors mediate seizures and CA1 hippocampal damage induced by dendrotoxin-K in rats, Neuroscience, 71, 613, 10.1016/0306-4522(95)00502-1 Li, 2006, Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice, J Pharmacol Exp Ther, 319, 254, 10.1124/jpet.106.103143 Belozertseva, 2007, Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests, Eur Neuropsychopharmacol, 17, 172, 10.1016/j.euroneuro.2006.03.002 Tu, 1999, Coupling of mGluR/Homer and PSD-95 complexes by the shank family of postsynaptic density proteins, Neuron, 23, 583, 10.1016/S0896-6273(00)80810-7 Alagarsamy, 1999, Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems, Nat Neurosci, 2, 234, 10.1038/6338 Palucha, 2005, Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist, Pharmacol Biochem Behav, 81, 901, 10.1016/j.pbb.2005.06.015 Hughes, 2013, Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression, Neuropharmacology, 66, 202, 10.1016/j.neuropharm.2012.04.007 Nakamoto, 2007, Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors, Proc Natl Acad Sci U S A, 104, 15537, 10.1073/pnas.0707484104 Harris, 2002, Acamprosate inhibits the binding and neurotoxic effects of Trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors, Alcohol Clin Exp Res, 26, 1779, 10.1111/j.1530-0277.2002.tb02484.x Palucha-Poniewiera, 2012, Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test, Prog Neuropsychopharmacol Biol Psychiatry, 39, 102, 10.1016/j.pnpbp.2012.05.015 Lejoyeux, 2011, Alcohol-use disorders and depression: Results from individual patient data meta-analysis of the acamprosate-controlled studies, Alcohol Alcohol, 46, 61, 10.1093/alcalc/agq077 Pecknold, 1982, Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study, J Clin Psychopharmacol, 2, 129, 10.1097/00004714-198204000-00010 Porter, 2005, Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity, J Pharmacol Exp Ther, 315, 711, 10.1124/jpet.105.089839 Lapierre, 1982, Fenobam: Another anxiolytic?, Curr Ther Res, 31, 95 Schoepp, 2001, Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system, J Pharmacol Exp Ther, 299, 12 Tamaru, 2001, Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites, Neuroscience, 106, 481, 10.1016/S0306-4522(01)00305-0 Feinberg, 2002, The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat, Pharmacol Biochem Behav, 73, 467, 10.1016/S0091-3057(02)00843-2 Matrisciano, 2008, Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats, Neuropharmacology, 55, 525, 10.1016/j.neuropharm.2008.05.014 Ahnaou, 2009, Modulation of group II metabotropic glutamate receptor (mGlu(2)) elicits common changes in rat and mice sleep-wake architecture, Eur J Pharmacol, 603, 62, 10.1016/j.ejphar.2008.11.018 Fell, 2011, J Pharmacol Exp Ther, 336, 165, 10.1124/jpet.110.172957 Chaki, 2004, MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity, Neuropharmacology, 46, 457, 10.1016/j.neuropharm.2003.10.009 Yoshimizu, 2006, An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats, Psychopharmacology (Berl), 186, 587, 10.1007/s00213-006-0390-7 Palucha-Poniewiera, 2010, On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039, Psychopharmacology (Berl), 212, 523, 10.1007/s00213-010-1978-5 Campo, 2011, Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression, J Neurogenet, 25, 152, 10.3109/01677063.2011.627485 Vizi, 2010, Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment, Br J Pharmacol, 160, 785, 10.1111/j.1476-5381.2009.00624.x Palucha, 2004, Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats, Neuropharmacology, 46, 151, 10.1016/j.neuropharm.2003.09.006 Stachowicz, 2009, The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems, Neuropharmacology, 57, 227, 10.1016/j.neuropharm.2009.06.005 Palucha, 2007, Activation of the mGlu7 receptor elicits antidepressant-like effects in mice, Psychopharmacology (Berl), 194, 555, 10.1007/s00213-007-0856-2 Palucha-Poniewiera, 2010, The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent, J Pharmacol Exp Ther, 334, 1066, 10.1124/jpet.110.169730 Pelkey, 2007, mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082, Neuropharmacology, 52, 108, 10.1016/j.neuropharm.2006.07.020 Sukoff Rizzo, 2011, The mGluR7 allosteric modulator AMN082: A monoaminergic agent in disguise?, J Pharmacol Exp Ther, 338, 345, 10.1124/jpet.110.177378 Palucha-Poniewiera, 2013, A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats, Behav Brain Res, 238, 109, 10.1016/j.bbr.2012.10.004 Banasr, 2010, Role of glial glutamate transporter GLT1 (EAAT2) in the antidepressant action of riluzole and ceftriaxone, Biol Psychiatry, 67 John, 2012, Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia, Neuropsychopharmacology, 37, 2467, 10.1038/npp.2012.105 Brennan, 2010, Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole, Neuropsychopharmacology, 35, 834, 10.1038/npp.2009.191 Coric, 2003, Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder, Psychopharmacology (Berl), 167, 219, 10.1007/s00213-003-1396-z Takahashi, 2011, Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression, Behav Brain Res, 216, 46, 10.1016/j.bbr.2010.07.002 Mathew, 2010, Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial, Int J Neuropsychopharmacol, 13, 71, 10.1017/S1461145709000169 Sanacora, 2007, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms, Biol Psychiatry, 61, 822, 10.1016/j.biopsych.2006.08.037 Zarate, 2004, An open-label trial of riluzole in patients with treatment-resistant major depression, Am J Psychiatry, 161, 171, 10.1176/appi.ajp.161.1.171 Rothstein, 2005, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression, Nature, 433, 73, 10.1038/nature03180 Mineur, 2007, Antidepressant-like effects of ceftriaxone in male C57BL/6J mice, Biol Psychiatry, 61, 250, 10.1016/j.biopsych.2006.04.037 Baker, 2002, Cystine/glutamate exchange serves as the source for extracellular glutamate: Modifications by repeated cocaine administration, Amino Acids, 23, 161, 10.1007/s00726-001-0122-6 Mcbean, 2002, Cerebral cystine uptake: A tale of two transporters, Trends Pharmacol Sci, 23, 299, 10.1016/S0165-6147(02)02060-6 Schmaal, 2012, N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: A randomized crossover magnetic resonance spectroscopy study, Neuropsychopharmacology, 37, 2143, 10.1038/npp.2012.66 Ferreira, 2008, Antidepressant-like effects of N-acetyl-L-cysteine in rats, Behav Pharmacol, 19, 747, 10.1097/FBP.0b013e3283123c98 Linck, 2012, AMPA glutamate receptors mediate the antidepressant-like effects of N-acetylcysteine in the mouse tail suspension test, Behav Pharmacol, 23, 171, 10.1097/FBP.0b013e3283512c3a Berk, 2008, N-acetyl cysteine for depressive symptoms in bipolar disorder - A double-blind randomized placebo-controlled trial, Biol Psychiatry, 64, 468, 10.1016/j.biopsych.2008.04.022